The heat on healthcare’s middlemen — pharmacy benefit managers (PBM) — is increasing, but a tangible solution may still be far off. Lawmakers grilled PBM executives Tuesday at the third hearing in a ...
In a conversation hosted by DSN, EmpiRx Health CEO Danny Sanchez and EmpiRx Health President John Ridyard detailed how their mid-market PBM is gaining traction by putting pharmacists at the center of ...
Bipartisan policies in Congress meant to lower drug costs by targeting middlemen in the pharmaceutical supply chain are likely to run up against a fundamental issue: the three major pharmacy benefit ...
Forbes contributors publish independent expert analyses and insights. I write about business model strategy and execution across healthcare. Corrected, July 23, 2024: An earlier version of this ...
The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission (FTC) released its second interim staff report on prescription drug middlemen. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results